6533b85bfe1ef96bd12bbfc8
RESEARCH PRODUCT
The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study
Malcolm J. WestAdrienne KirbyHarvey D. WhiteChristine PollicinoRenate B. SchnabelPaul J. NestelEdith LubosAndrew TonkinBlankenberg StefanR. John SimesThomas MünzelLaurence TiretDavid R. SullivanChristoph Bickelsubject
AdultMalemedicine.medical_specialtymedicine.drug_classMyocardial InfarctionCoronary AngiographyGastroenterologyLeukocyte CountRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansAngina UnstableAgedPravastatinTissue Inhibitor of Metalloproteinase-1Framingham Risk Scorebusiness.industryAnticholesteremic AgentsCase-control studyOdds ratioMiddle AgedPrognosisBrain natriuretic peptidePeptide FragmentsC-Reactive ProteinEndocrinologyQuartileCase-Control StudiesNested case-control studyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersPravastatinmedicine.drugdescription
Aims We sought to determine the association between two major biomarkers, the inactive N-terminal fragment of brain natriuretic peptide (NT-proBNP) and tissue inhibitor of metalloproteinase-1 (TIMP-1) and long-term cardiovascular outcomes in a cohort of subjects who had a myocardial infarction or unstable angina 3–36 months previously. Methods and results Plasma NT-proBNP and TIMP-1 were measured in a nested case control study of 250 randomly matched subject pairs enrolled in the long-term intervention with pravastatin in ischaemic disease (LIPID) and LIPID extended follow-up studies. Cases ( n = 250) were defined as those who had a cardiovascular death, non-fatal myocardial infarction or stroke during the studies. Controls ( n = 250) remained event-free for the same follow-up duration (average 2.5 years) as the matched cases. The relationships between cases and plasma NT-proBNP and TIMP-1 were adjusted for the LIPID risk score, treatment allocation and other biomarkers (CRP, IL-6 and white cell count), and examined using a multivariable conditional logistic regression model. NT-proBNP levels were significantly higher in the cases than in the controls [389 (152–864) vs. 198 (93–416) pg/mL, median (25%–75% percentiles), P < 0.001]. The odds ratio (OR) of recurrent cardiovascular events in individuals in the highest quartile was three times higher than those in the lowest quartile (95% confidence interval (CI) 1.8–5.1; P < 0.001). Similarly, TIMP-1 levels were significantly higher among cases compared with controls (806 vs. 736 pg/mL, median: highest vs. lowest quartile: OR 2.8, 95% CI 1.6–4.7; P < 0.001). After adjustment for the LIPID risk score, treatment with pravastatin and other biomarkers, both NT-proBNP and TIMP-1 predicted cardiovascular events significantly and independently of each other. Conclusion The study suggests that in subjects with stable ischaemic disease, NT-proBNP and TIMP-1 are independent predictive markers of coronary heart disease outcome.
year | journal | country | edition | language |
---|---|---|---|---|
2008-02-26 | European Heart Journal |